Thermo Fisher Scientific
National Cancer Institute Launches MyeloMATCH Myeloid Cancer Treatment Clinical Trial
The trial aims to enroll several thousand patients to test precision medicine treatments for bone marrow and blood cancers.
FDA Approves Thermo Fisher Oncomine Dx Target Test as CDx for Servier's Voranigo Brain Cancer Drug
The approval expands the clinical indications for the test, which was previously approved as a CDx for non-small cell lung cancer, thyroid cancer, and bile duct cancer drugs.
FDA Approves Servier's Voranigo for Certain IDH-Mutated Gliomas
The approval marks the first targeted therapy commercially available for patients with grade 2 IDH-mutated glioma.
FDA Approves Thermo Fisher Scientific HLA Typing Kit as CDx for Adaptimmune T-Cell Receptor Therapy
Adaptimmune's therapy is intended to treat patients with unresectable or metastatic synovial sarcoma who have received prior chemotherapy.
FDA Approves Adaptimmune's TCR Therapy Tecelra for Certain Synovial Sarcoma Patients
The accelerated approval marks the first time the FDA has approved an engineered autologous cell therapy for a solid tumor indication.